Miguel Ángel
González-Gay Mantecón

2024

1. A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

   Arthritis and Rheumatology, Vol. 76, Núm. 11, pp. 1623-1634

2. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

   Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

3. Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease

   Antioxidants, Vol. 13, Núm. 10

4. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

   RMD Open, Vol. 10, Núm. 3

5. Biopsy-proven giant cell arteritis in an elderly woman diagnosed 11 years earlier with microscopic polyangiitis: two different vasculitides in the same patient separated in time

   Clinical and Experimental Rheumatology

6. Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease

   Expert Review of Clinical Immunology, Vol. 20, Núm. 9, pp. 1089-1100

7. Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up

   Seminars in Arthritis and Rheumatism, Vol. 66

8. Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting

   Vaccines, Vol. 12, Núm. 6

9. Genetics of vasculitis

   Best Practice and Research: Clinical Rheumatology

10. Inflammasome-Related Genetic Polymorphisms as Severity Biomarkers of COVID-19

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

11. Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis

    Kidney International Reports, Vol. 9, Núm. 6, pp. 1817-1835

12. Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 42, Núm. 8, pp. 1564-1570

13. Issues in the classification of myositis patients: an ongoing process

    Clinical and experimental rheumatology

14. Leflunomide as a therapeutic alternative to methotrexate as a glucocorticoid-sparing agent in polymyalgia rheumatica

    Rheumatology Advances in Practice

15. Lights and shadows on the efficacy of tocilizumab monotherapy in large vessel giant cell arteritis

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 6-7

16. Malondialdehyde Serum Levels in a Full Characterized Series of 430 Rheumatoid Arthritis Patients

    Journal of Clinical Medicine, Vol. 13, Núm. 3

17. Mean Platelet Volume Is Related to Cumulative Disease Damage in Patients with Systemic Lupus Erythematosus

    Life, Vol. 14, Núm. 4

18. Metabolic Syndrome: A Predisposing Factor for Rheumatoid Arthritis

    Journal of Rheumatology

19. Osteopontin as a Biomarker in Interstitial Lung Diseases

    Biomedicines, Vol. 12, Núm. 5

20. Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs

    Biomedicine and Pharmacotherapy, Vol. 173